41.4 F
New York
Sunday, February 28, 2021

BeiGene [NASDAQ: BGNE] Signs Licensing Deal For Neutralizing COVID-19 Antibodies With Singlomics

Must read

ChargePoint Inc [NYSE: CHPT] Announces The Completion Of Business Combination With SwithBack Energy

ChargePoint Inc revealed that the company has completed its business merger with Switchback Energy Acquisition Corp. Additionally, The companies uncover the close of...

Bank of America [NYSE: BAC] Announced Paid Break For Employees For Covid Vaccination

Bank Of America Corp  announced that the company will give its staff paid time off for covid vaccination. Moreover, the company states that...

Fidelity D and D Bancorp [NASDAQ: FDBC] Executes Acquisition Of Landmark Bancorp

Fidelity D and D Bancorp, Inc. announced the acquisition of Landmark Bancorp, Inc. The company reported executing the contract in which Landmark will...

Atlassian Corp [NYSE: TEAM] Announces The Acquisition Of Chartio

Atlassian Corporation announced the acquisition of Chartio. The acquisition of Chartio to the Atlassian stage will give a robust analytic experience across our...

BeiGene, Ltd. [NASDAQ: BGNE] and Singlomics Biopharmaceuticals, Ltd both entered into an exclusive license agreement for neutralizing COVID-19 antibodies.

The license agreement will allow BeiGene to develop, manufacture, and commercialize Singlomics’ investigational anti-COVID-19 antibodies, including DXP-593 and DXP-604 globally. 

Shares of BeiGene had plummeted 0.63%, or down -1.58 during the trading of Wednesday. It has a closing price of $249.26. BeiGene had recorded the trading volume of 128.02K as compared to the average volume of 272.07K.

In the past 52-weeks of trading BeiGene’s stocks have changed between the low and high of $114.41-$256.01, respectively. It has exhibited the highest change of 117.87% from its 52-weeks low and the lowest change of -2.64% from its 52-weeks high.

If we turn our focus o its profitability, it has return on assets (ROA), return on equity (ROE), and return on investment (ROI) of -48.70%, -73.50%, and -85.60%, respectively.

Its Gross Margin is 70.40%. Continuing to look at its liquidity, it has a current ratio of 6.20. Similarly, its quick ratio is 6.10. This company has a total market capitalization of 21.75 billion.

Singlomics Biopharmaceutical has recognized multiple antibodies by using single-cell sequencing of convalescent blood samples from recovered patients with COVID-19.

It has shown the ability to neutralize the SARS-CoV-2, the virus that caused COVID-19 in the pre-clinical studies. Singlomics strived to find the potent neutralizing antibodies to develop a treatment.

BeiGene has a strong background in clinical development and the new agreement will give an opportunity to the companies to develop the potential treatment for COVID-19.

A phase 1 clinical trial is anticipated to commence in September with up to 30 healthy patients. Additionally, the phase 1/2 multinational trial with mild to moderate COVID-19 will also commence in October.

Singlomics will get an upfront payment. It will also receive payments upon the achievement of regulatory and commercial milestones.

Furthermore, Singlomics will also get tiered royalties, up to double-digits, on future product sales.

More articles

Latest article

MongoDB [NASDAQ: MDB] Announces Extended 5-year Collaboration With Google Cloud

MongoDB Inc. , reported an extended five-year collaboration that will stretch out their current go-to-market relationship. Moreover, it will provide a more profound integration...

Humana Inc [NYSE: HUM] Announces Collaboration With Mercy

Mercy and  Humana Inc. announces that the companies have collaborated. Both the companies inked a contract to extend patient access to virtual healthcare...

International Paper [NYSE: IP] Reports Purchase Of Berkley MF LLC

International Paper has purchased Berkley International's Molded Fiber (Pulp) production subsidiary, Berkley MF LLC. Berkley is the provider of essential packaging and e-commerce...

Perspecta [NYSE: PRSP] Received an Award For $38 Million To Continue Supporting DMDC

Perspecta Inc. , reported that the company has been granted an award to keep supporting the Defense Manpower Data Center (DMDC) with a strategic...

SG Blocks [NASDAQ: SGBX] Continues Growth Through The Execution Of 19-acre Acquisition Contract

SG Blocks, Inc. executes the contract to purchase the 19 acre Echo sites and all of its multiple structures. The company reported the...

HP Inc [NYSE: HPQ] Enters Into A Contract To Purchase HyperX

HP Inc. revealed that the company entered into a contract to purchase HyperX. It is the gaming subsidiary of Kingston Technology Company. Moreover,...

AT&T [NYSE: T] Might Sell Its Large Minority Stake At Direct TV/ U-Verse Operation To TPG

AT&T is approaching a deal to sell a significant minority stake in its DirecTV, AT&T TV Now, and U-Verse business to TPG. Additionally,...

Wipro [NYSE: WIT] Entered Into A Collaborative Agreement With Uptake

Uptake revealed that the company has collaborated with Wipro limited . The companies inked the agreement to deliver industrial intelligence for the utilities, chemical...